Method for treating heart failure
The present disclosure relates to methods for treating or preventing heart failure in subjects with elevated left ventricular end systolic volume (LVESV). In particular, the present disclosure relates to methods for treating or preventing heart failure in subjects with a LVESV of greater than 70 ml (>70 ml).
1. A method for treating chronic heart failure due to left ventricular systolic dysfunction in a human subject characterized by: (i) an elevated baseline left ventricular end systolic volume (LVESV) of greater than 100 mL, and (ii) a baseline left ventricular ejection fraction (LVEF) of less than or equal to 35%, the method comprising administering to the myocardium of the human subject's heart a population of about 75-150 million mesenchymal lineage precursor cells (MPCs) expressing STRO-1+ and STRO-3+ so as to improve the human subject's LVESV and left ventricular end diastolic volume (LVEDV) by:
(a) reducing the LVESV by at least 8 mL relative to the subject's baseline LVESV volume; and (b) reducing the LVEDV by at least 10 mL relative to the subject's baseline LVEDV volume, so as to treat the subject's chronic heart failure, wherein (a) and (b) are measured at 6 months after administration of the MPCs.
2. The method of claim 1 , wherein:
(i) the elevated LVESV is due to acute myocardial infarction; or
(ii) the elevated LVESV is due to chronic congestive heart failure.
3. The method according to claim 1 , wherein the subject has an LVESV of greater than 110 mL.
4. The method according to claim 1 , wherein the population of MPCs is administered to the subject by a catheter-based system.
5. The method according to claim 4 , wherein the population of MPCs is administered to the subject by transendocardial injection, intracoronary infusion, intravenous infusion or transepicardial injection.
6. The method according to claim 1 , wherein the heart failure is due to hypertension, ischemic or non-ischemic cardiomyopathy, myocarditis, obesity, or diabetes.
7. The method according to claim 1 , wherein the population of MPCs is administered to the subject between about 1 day and 7 days following a diagnosis of heart failure.
8. The method according to claim 1 , comprising administering a population of about 150 million MPCs to the subject in a single dose or over multiple doses.
9. The method according to claim 1 , wherein the population of MPCs is administered to the subject in the form of a composition comprising a pharmaceutically acceptable carrier and/or excipient.
10. The method according to claim 1 , wherein the population of MPCs is autologous or allogeneic.
11. The method according to claim 1 , wherein the MPCs are STRO-1 bright cells.